OncoMatch/Clinical Trials/NCT07680868
Caris Chromoseq Data Collection
Is NCT07680868 recruiting? Yes, currently enrolling (Jul 2026).
The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk stratification for patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). The hypothesis of the study is that Caris Chromoseq compares favorably to conventional cytogenetics, FISH, and NGS analysis in terms of risk stratification capabilities, ease of use, and turnaround time.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myeloproliferative Neoplasm
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Caris Life Sciences · Phoenix, Arizona
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07680868 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify